SCHEMBL24539728

SCHEMBL24539728

c1ccc(-c2ccccc2N(c2cccc(-c3cccc4c5ccc6oc7ccccc7c6c5c5ccccc5c34)c2)c2cccc3ccccc23)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A1 P04798 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ FYN P06241 1/20 0.32
▸ MAPK3 P27361 1/20 0.32
▸ AHR P35869 1/20 0.32
▸ PAX8 Q06710 1/20 0.32
▸ ABCG2 Q9UNQ0 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ CYP1B1 Q16678 1/20 0.32
▸ KDM4E B2RXH2 2/20 0.31
▸ ALDH1A1 P00352 2/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ CASP1 P29466 1/20 0.31
▸ CASP7 P55210 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31
▸ MAOB P27338 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27011880 0.96 L3MBTL1 (0.35) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539744 0.94 ABCG2 (0.33) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539758 0.93 CYP1A1 (0.33) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539750 0.92 PLA2G2A (0.34) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL27011995 0.92 CYP1A1 (0.32) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539822 0.91 TDP1 (0.33) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539749 0.91 ALOX5 (0.32) CYP1A1CYP1A2ABCG2CYP1B1HPGD
SCHEMBL27011391 0.91 PLA2G2A (0.34) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539731 0.91 CYP1A1 (0.32) CYP1A1CYP1A2FYNMAPK3AHR
SCHEMBL24539738 0.91 CYP1A1 (0.32) CYP1A1CYP1A2FYNMAPK3AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 — — US disclosed
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER LT MATERIALS CO., LTD. (KR) 2024-01-18 — — US disclosed
WO-2022131546-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER 엘티소재주식회사 2022-06-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240023432-A1 HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME, MANUFACTURING METHOD THEREFOR, AND COMPOSITION FOR ORGANIC LAYER CYP1B1, NOTUM, CYP4F11 CYP1A1 7/4885CYP1A2 63/4885FYN 3026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback